ChinamedLink

27/12/2025

From Despair to Hope: Malaysian Patient with Terminal Lung Cancer and Brain Metastasis Finds New Life in China.

26/12/2025

26/12/2025

Big breakthrough for Stage IIB-III MSI-H/dMMR colon cancer patients around the world!

🇨🇳 NMPA Approved | WORLD’S FIRST & ONLY Dual Immunotherapy (Daboxin®+Dabenli®) for Resectable Stage IIB-III MSI-H/dMMR Colon Cancer (Neoadjuvant)

✅ 82%+ pCR rate, drastically reduce postoperative chemo burden
✅ Target CTLA-4 + PD-1, synergistic anti-tumor efficacy
✅ Exclusive access in China for overseas patients

👉 China is the global pioneer of colon cancer dual immunotherapy neoadjuvant treatment!

🎉JOYFUL Medical are all Chinese professionals who have worked in China's medical field for more than ten years.

We are not just a simple medical referral agency. We integrate China's top - tier medical resources to offer patients the best treatment plans.

We aim to build an all-round bridge, enabling overseas patients to smoothly enjoy the benefits brought by China's innovative medicines, high-level medical services and efficient diagnosis and treatment processes, and to feel the warmth of home in a foreign country.

Website: http://www.shjoyfulmed.com

Email: info@shjoyfulmed.com

Whatsapp: +86 15212221605

25/12/2025

Three Colombian neurosurgeons observed an 8-contact DBS surgery led by Professor Hu Xiaowu and Director Zeng Ran at the Neuromodulation/Parkinson’s Academic Center of Donglei Brain Hospital. This procedure showcased China’s prowess in neurological care to the international medical community. A pioneer in Shanghai for this technology, the Donglei team has leveraged 8-contact DBS to overcome limitations of conventional therapies, markedly improving refractory symptoms like freezing of gait in Parkinson’s patients and restoring their mobility.

25/12/2025

Maureen's Cancer Battle
Hope in China
Maureen (Kenya): Stage III pancreatic cancer, given up😂.
Cross-Ocean Hope Turned to Guangzhou Fuda, 54kg weak.
💯Treatment Breakthrough The medical team developed a comprehensive plan: Nanoknife Ablation + Interventional Therapy + Immunotherapy. The Nanoknife procedure was completed in just 1 hour, subverting her previous perception of an 8-hour treatment.
🥰After surgery, she quickly regained appetite, slept soundly, regained weight, and her cancer pain eased.
👏Her former doctor in India was shocked by her "rebirth"—most of the tumor lesions had necrosed.4. Miracle Unfolds Pain eased, weight back, lesions necrosed.
🎉Spreading Hope Now living independently with full vitality, she encourages other cancer patients: "In the darkest moments, never give up the search for light."

🎉JOYFUL Medical are all Chinese professionals who have worked in China's medical field for more than ten years.

We are not just a simple medical referral agency. We integrate China's top - tier medical resources to offer patients the best treatment plans.

We aim to build an all-round bridge, enabling overseas patients to smoothly enjoy the benefits brought by China's innovative medicines, high-level medical services and efficient diagnosis and treatment processes, and to feel the warmth of home in a foreign country.

Website: http://www.shjoyfulmed.com

Email: info@shjoyfulmed.com

Whatsapp: +86 15212221605

05/12/2025

Treatment progress for triple-negative breast cancer in China.
1. For neoadjuvant treatment of triple-negative breast cancer, the pathological complete response rate of camrelizumab combined with chemotherapy increased by 15.6% compared with chemotherapy alone (from 27.4% to 43.0%). Relevant data were published in Journal of Clinical Oncology.
Lucancatumab (a new ADC) for advanced triple-negative breast cancer extended the median progression-free survival by 4.2 months (from 5.8 months to 10.0 months) and was recommended in China Breast Cancer Diagnosis and Treatment Guidelines.
The "Fudan Classification" matches regimens for patients with different subtypes: For the immunomodulatory subtype, PD-1 inhibitor combined with chemotherapy achieved an objective response rate of 68.3%; for the luminal androgen subtype, AR antagonists increased the disease control rate to 82.7%.

http://www.shjoyfulmed.com
📩 For eligibility checks and enrollment support: info@shjoyfulmed.com

WeChat / WhatsApp: +86 150 2673 8002

JOYFUL Medical | Advanced Cancer Treatment Management

🇨🇳

04/12/2025

Clinical Trials Alert | Chinese Academy of Medical Sciences, National Cancer Center

A new recruitment call is now open for a promising lung cancer clinical trial in China. Researchers at the National Cancer Center are evaluating a combination of inhaled mRNA vaccine with bevacizumab (VEGF/PD-1 bispecific antibody).

This study is enrolling patients with:
• Chemotherapy-resistant lung cancer
• Adenocarcinoma or squamous cell carcinoma
• Cases with or without genetic mutations

The trial aims to investigate whether this dual-immunotherapy approach can enhance anti-tumor activity and open new options for patients who have limited treatment choices left.

If you or someone you know is seeking advanced treatment pathways, this may be worth considering.

http://www.shjoyfulmed.com
📩 For eligibility checks and enrollment support: info@shjoyfulmed.com

WeChat / WhatsApp: +86 150 2673 8002

JOYFUL Medical | Advanced Cancer Treatment Management

04/12/2025

Our team are all chinese professionals who have worked in China's medical field for more than ten years.

We are familiar with China's medical resources and Chinese doctors and can accurately match the most suitable departments and doctors.

We are not just a simple medical referral agency. We integrate China's top - tier medical resources to offer patients the best treatment plans.

We aim to build an all-round bridge, enabling overseas patients to smoothly enjoy the benefits brought by China's innovative medicines, high-level medical services and efficient diagnosis and treatment processes, and to feel the warmth of home in a foreign country.

Website: http://www.shjoyfulmed.com

Email: info@shjoyfulmed.com

Whatsapp: +86 150 2673 8002

03/12/2025

CyberKnife, also known as the "Stereotactic Radiosurgery Platform", is an advanced device used for radiotherapy of tumors in various parts of the body.

It has a remarkably significant therapeutic effect on meningioma, acoustic neuroma, brain metastases, liver cancer, lung cancer, osteosarcoma, etc.

There are several hospitals in Guangzhou, China, that we cooperate with and are equipped with this device.

After price comparison, the cost - performance ratio of one particular hospital stands out.

A large number of international patients have seen hope in tumor treatment at this hospital.

For world-class, reliable cancer care in China, connect with us.
🌐 Website: http://www.shjoyfulmed.com
📧 Email: info@shjoyfulmed.com
📱 Whatsapp: +86 150 2673 8002